- To

Dkt. 60921-A/JPW/MVM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

licant : Ira Tabas

Serial No. : 10/767,749 Examiner: B.E. Bunner

Filing Date : January 28, 2004 Art Unit: 1647

For : METHODS FOR PREVENTING ACUTE CLINICAL

VASCULAR EVENTS IN A SUBJECT

1185 Avenue of the Americas New York, New York 10036 August 20, 2007

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicant directs the Examiner's attention to the following references which are listed on the attached Substitute Form PTO-1449 (Exhibit A). Copies of these references are attached hereto as Exhibits 1-68, respectively.

- 1. U.S. Application Serial No. 09/553,927 filed April 21, 2000, on behalf of Tabas et al. (now abandoned) (Exhibit 1);
- 2. U.S. Patent Application Publication No. US2003/0235878 A1 published December 25, 2003, on behalf of Tabas et al. (now abandoned);
- 3. PCT International Application No. PCT/US2001/012877, filed April 20, 2001, publication No. WO 2001/080715 A3, published

08/24/2007 SFELEKE1 00000001 10767749

01 FC:1806

180.00 OP

Filed : January 28, 2004

Page 2

November 1, 2001 on behalf of The Trustees of Columbia University in the City of New York (Exhibit 2);

- 4. PCT International Application No. PCT/US2003/013164, filed April 30, 2003, publication No. WO 2003/092467 A3, published November 13, 2003 on behalf of The Trustees of Columbia University in the City of New York (Exhibit 3);
- 5. December 22, 2006 International Preliminary Examination Report issued in connection with PCT International Application No. PCT/US2001/12877, filed April 20, 2001 (Exhibit 4);
- 6. Aikawa, K., et al. (1994) "Structure-specific Inhibition of Lysosomal Cholesterol Transport in Macrophages by Various Steriods," *Biochim. Biophys. Acta.* 1213: 127-134 (Exhibit 5);
- 7. Arends, M.J., et al. (1991) "Apoptosis: Mechanisms and Roles in Pathology," Int. Rev. Exper. Pathol. 32: 223-254 (Exhibit 6);
- 8. Basu, S.K., et al. (1976) "Degradation of Cationized Low Density Lipoprotein and Regulation of Cholesterol Metabolism in Homozygous Familial Hypercholesterolemia Fibroblasts,"

 Proc. Natl. Acad. Sci. U.S.A. 73: 3178-3182 (Exhibit 7);
- 9. Bertolotti, A., et al. (2000) "Dynamic Interaction of BiP and ER Stress Transducers in the Unfolded-protein Response," Nat. Cell Biol. 2: 326-332 (Exhibit 8);
- 10. Bjorkhem, I., et al. (1994) "Atherosclerosis and Sterol 27-Hydroxylase: Evidence for a Role of This Enzyme in Elimination

Filed : January 28, 2004

Page 3

of Cholesterol From Human Macrophages, " Proc. Natl. Acad. Sci. U.S.A. 91: 8592-8596 (Exhibit 9);

- 11. Brown, M.S., et al. (1983) "Lipoprotein Metabolism in the
 Macrophage: Implications for Cholesterol Deposition in
 Atherosclerosis¹, " Annu. Rev. Biochem. 52: 223-261 (Exhibit
 10);
- 12. Brown, M.S., et al. (1997) "The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor," Cell 89: 331-340 (Exhibit 11);
- 13. Calfon, M., et al. (2002) "IRE1 Couples Endoplasmic Reticulum Load to Secretory Capacity by Processing the XBP-1 mRNA,"

 Nature 415: 92-96 (Exhibit 12);
- 14. Chang, M.-K., et al. (1999) "Monoclonal Antibodies Against Oxidized Low-density Lipoprotein Bind to Apoptotic Cells and Inhibit Their Phagocytosis by Elicited Macrophages: Evidence that Oxidation-specific Epitopes Mediate Macrophage Recognition," Proc. Natl. Acad. Sci. U.S.A. 96: 6353-6358 (Exhibit 13);
- 15. Devlin, C., et al. (2002) "Genetic Alterations of IL-1 Receptor Antagonist in Mice Affect Plasma Cholesterol Level and Foam Cell Lesion Size," *Proc. Natl. Acad. Sci. U.S.A.* 99: 6280-6285 (Exhibit 14);
- 16. Feng, B., et al. (2003) "The Endoplasmic Reticulum is the Site of Cholesterol-induced Cytotoxicity in Macrophages," Nat. Cell Biol. 5: 781-792 (Exhibit 15);

Filed : January 28, 2004

- 17. Feng, B., et al. (2003) "Niemann-Pick C Heterozygosity Confers Resistance to Lesional Necrosis and Macrophage Apoptosis in Murine Atherosclerosis," PNAS 100: 10423-10428 (Exhibit 16);
- 18. Fuster, V., et al. (1992) "The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes: (First of Two Parts)," N. Engl. J. Med. 326: 242-250 (Exhibit 17);
- 19. Graham, J.M., et al. (1970) "The Properties of Mitochondria Enriched in vitro with Cholesterol," Eur. J. Biochem. 12: 58-66 (Exhibit 18);
- 20. Green, D.R. (1998) "Apoptotic Pathways: The Roads to Ruin,"

 Cell 94: 695-698 (Exhibit 19);
- 21. Guyton, J.R., et al. (1996) "Development of the Lipid-Rich Core in Human Atherosclerosis," Arterioscler. Thromb. Vase.

 Biol. 16: 4-11 (Exhibit 20);
- 22. Harding, H.P., et al. (1999) "Protein Translation and Folding are Coupled by an Endoplasmic-reticulum-resident Kinase,"

 Nature 397: 271-274 (Exhibit 21);
- 23. Harding, H.P., et al. (2000) "Perk is Essential for Translational Regulation and Cell Survival during the Unfolded Protein Response," Mol. Cell 5: 897-904 (Exhibit 22);
- 24. Harding, H.P., et al. (2000) "Regulated Translation Initiation Controls Stress-Induced Gene Expression in Mammalian Cells,"

 Mol. Cell 6: 1099-1108 (Exhibit 23);

Filed : January 28, 2004

- 25. Harding, H.P., et al. (2001) "Diabetes Mellitus and Exocrine Pancreatic Dysfunction in Perk-I- Mice Reveals a Role for Translational Control in Secretory Cell Survival," Mol. Cell 7: 1153-1163 (Exhibit 24);
- 26. Kockx, M.M., et al. (1998) "RNA Synthesis and Splicing Interferes with DNA in Situ End Labeling Techniques Used to Detect Apoptosis," Am. J. Pathol. 152: 885-888 (Exhibit 25);
- 27. Kockx, M.M. (1998) "Apoptosis in the Atherosclerotic Plaque:
 Quantitative and Qualitative Aspects," Arterioscler. Thromb.
 Vase. Biol. 18: 1519-1522 (Exhibit 26);
- 28. Kruth, H.S. (1985) "Subendothelial Accumulation of Unesterified Cholesterol: An Early Event in Atherosclerotic Lesion Development," Atherosclerosis 57: 337-341 (Exhibit 27);
- 29. Kruth, H.S., et al. (1986) "Type C Niemann-pick Disease: Abnormal Metabolism of Low Density Lipoprotein in Homozygous and Heterozygous Fibroblast*," J. Biol. Chem. 261: 16769-16774 (Exhibit 28);
- 30. Lemasters, J. J. (1999) "Mechanisms of Hepatic Toxicity V. Necrapoptosis and the Mitochondrial Permeability Transition: Shared Pathways to Necrosis and Apoptosis*," Am. J. Physiol. 276: G1-G6 (Exhibit 29);
- 31. Liscum, L., et al. (1992) "Intracellular Cholesterol Transport," J. Lipid Res. 33: 1239-1254 (Exhibit 30);

Filed : January 28, 2004

- 32. Lopes-Virella, M.F., et al. (1992) "Immune Mechanisms of Atherosclerosis in Diabetes Mellitus," *Diabetes* 41 (Suppl. 2): 86-91 (Exhibit 31);
- 33. Majno, G., et al. (1995) "Apoptosis, Oncosis, and Necrosis: An Overview of Cell Death," Am. J. Pathol. 146: 3-15 (Exhibit 32);
- 34. Matsuda, K. (1994) "ACAT Inhibitors as Antiatherosclerotic Agents: Compounds and Mechanisms," Med. Res. Rev. 14: 271-305 (Exhibit 33);
- 35. Maxfield, F.R. (2002) "Intracellular Cholesterol Transport,"

 J. Clin. Invest. 110: 891-898 (Exhibit 34);
- 36. McCullough, K.D., et al. (2001) "Gadd153 Sensitizes Cells to Endoplasmic Reticulum Stress by Down-Regulating Bc12 and Perturbing the Cellular Redox State," Mol. Cell Biol. 21: 1249-1259 (Exhibit 35);
- 37. Nakagawa, T., et al. (2000) "Caspase-12 Mediates Endoplasmic-reticulum-specific Apoptosis and Cytotoxicity by Amyloid- β ,"

 Nature 403: 98-103 (Exhibit 36);
- 38. Nakashima, Y., et al. (1994) "ApoE-Deficient Mice Develop Lesions of All Phases of Atherosclerosis Throughout the Arterial Tree," Arterioscler. Thromb. 14: 133-140 (Exhibit 37);
- 39. Nishitoh, H., et al. (2002) "ASK1 is Essential for Endoplasmic Reticulum Stress-induced Neuronal Cell Death Triggered by Expanded Polyglutamine Repeats," Genes Dev. 16:

Filed : January 28, 2004

Page 7

1345-1355 (Exhibit 38);

- 40. Oyadomari, S., et al. (2002) "Targeted Disruption of the Chop Gene Delays Endoplasmic Reticulum Stress-mediated Diabetes," J. Clin. Invest. 109: 525-532 (Exhibit 39);
- 41. Papahadjopoulos, D. (1974) "Cholesterol and Cell Membrane Function: A Hypothesis Concerning the Etiology of Artherosclerosis," J. Theor. Biol. 43: 329-337 (Exhibit 40);
- 42. Patil, C., et al. (2001) "Intracellular Signaling from the Endoplasmic Reticulum to the Nucleus: The Unfolded Protein Response in Yeast and Mammals," Curr. Opin. Cell Biol. 13: 349-356 (Exhibit 41);
- 43. Pentchev, P.G., et al. (1984) "A Genetic Storage Disorder in BALB/C Mice with a Metabolic Block in Esterification of Exogenous Cholesterol*," J. Biol. Chem. 259: 5784-5791 (Exhibit 42);
- 44. Pentchev, P.G., et al. (1997) "Biological Implications of the Niemann-Pick C Mutation," Sub-Cell. Biochem. 28: 437-451 (Exhibit 43);
- 45. Reddick, R.L., et al. (1994) "Atherosclerosis in Mice Lacking Apo E: Evaluation of Lesional Development and Progression," Arterioscler. Thromb. 14: 141-147 (Exhibit 44);
- 46. Ross, A.C., et al. (1984) "Selective Inhibition of Acyl Coenzyme A: Cholesterol Acyltransferase by Compound 58-035*,"

 J. Biol. Chem. 259: 815-819 (Exhibit 45);

Filed : January 28, 2004

- 47. Ross, D.D., et al. (1989) "Estimation of Cell Survival by Flow Cytometric Quantification of Fluorescein Diacetate/Propidium Iodide Viable Cell Number¹," Cancer Res. 49: 3776-3782 (Exhibit 46);
- 48. Small, D.M., et al. (1984) "Physicochemical and Histological Changes in the Arterial Wall of Nonhuman Primates during Progression and Regression of Atherosclerosis," *J. Clin. Invest.* 73: 1590-1605 (Exhibit 47);
- 49. Smith, J. D., et al. (1995) "Decreased Atherosclerosis In Mice Deficient In Both Macrophage Colony-stimulating Factor (op) and Apoliprotein E," Proc. Natl. Acad. Sci. U.S.A. 92: 8264-8268 (Exhibit 48);
- 50. Tabas, I., et al. (1988) "Rabbit Liver Microsomal ACAT: Smooth ER Enzyme Associated With A Lipid ACAT Inhibitor,"

 Arteriosclerosis 8: 559A (Exhibit 49);
- 51. Tang, W.A., et al. (1999) "Macrophage-targeted CTP: Phosphocholine Cytidylyltransferase (1-314) Transgenic Mice,"

 Biochim. Biophys. Acta 1437: 301-316 (Exhibit 50):
- 52. Travers, K.J., et al. (2000) "Functional and Genomic Analyses Reveal an Essential Coordination between the Unfolded Protein Response and ER-Associated Degradation," Cell 101: 249-258 (Exhibit 51);
- 53. Treiman, M. (2002) "Regulation of the Endoplasmic Reticulum Calcium Storage During the Unfolded Protein Response-Significance in Tissue Ischemia?" *Trends Cardiovasc. Med.* 12: 57-62 (Exhibit 52);

Filed : January 28, 2004

- 54. Urano, F., et al. (2000) "Coupling of Stress in the ER to Activation of JNK Protein Kinases by Transmembrane Protein Kinases IRE1," Science 287: 664-666 (Exhibit 53);
- 55. Wang, X.Z., et al. (1996) "Stress-Induced Phosphorylation and Activation of the Transcription Factor CHOP (GADD153) by p38 MAP Kinase, " Science 272: 1347-1349 (Exhibit 54);
- 56. Warner, G.J., et al. (1995) "Cell Toxicity Induced by Inhibition of Acyl Coenzyme A: Cholesterol Acyltransferase and Accumulation of Unesterified Cholesterol*," J. Biol. Chem. 270: 5772-5778 (Exhibit 55);
- 57. Yoshida, H. (2001) "XBP1 mRNA is Induced by ATF6 and Spliced by IRE1 in Response to ER Stress to Produce a Highly Active Transcription Factor," Cell 107: 881-891 (Exhibit 56);
- 58. Zhang, C., et al. (1998) "A Cell Surface Receptor Defined by a mAb Mediates A Unique Type of Cell Death Similar to Oncosis,"

 Proc. Natl. Acad. Sci. U.S.A. 95: 6290-6295 (Exhibit 57);
- 59. Zhang, P., et al. (2002) "The PERK Euraryotic Initiation Factor 2α Kinase Is Required for the Development of Sketetal System, Postnatal Growth, and the Function and Viability of the Pancreas," Mol. Cell Biol. 22: 3864-3874 (Exhibit 58);
- 60. Zinszner, H., et al. (1998) "CHOP is Implicated in Programmed Cell Death in Response to Impaired Function of the Endoplasmic Reticulum," Genes Dev. 12: 982-995 (Exhibit 59);

Filed : January 28, 2004

- 61. May 7, 2001 Office Action issued by the United States Patent and Trademark Office in connection with U.S. Application Serial No. 09/553,927, filed April 21, 2000 (Exhibit 60);
- 62. March 8, 2002 Final Office Action issued by the United States
 Patent and Trademark Office in connection with U.S.
 Application Serial No. 09/553,927, filed April 21, 2000
 (Exhibit 61);
- 63. September 9, 2002 Advisory Action issued by the United States
 Patent and Trademark Office in connection with U.S.
 Application Serial No. 09/553,927, filed April 21, 2000
 (Exhibit 62);
- 64. July 29, 2003 Office Action issued by the United States Patent and Trademark Office in connection with U.S. Application Serial No. 09/553,927, filed April 21, 2000 (Exhibit 63);
- 65. September 21, 2005 Office Action issued by the United States
 Patent and Trademark Office in connection with U.S.
 Application Serial No. 10/426,415, filed April 21, 2000
 (Exhibit 64);
- 66. March 24, 2006 Office Action issued by the United States
 Patent and Trademark Office in connection with U.S.
 Application Serial No. 10/426,415, filed April 21, 2000
 (Exhibit 65);
- 67. October 4, 2006 Office Action issued by the United States
 Patent and Trademark Office in connection with U.S.
 Application Serial No. 10/426,415, filed April 21, 2000
 (Exhibit 66);

Filed : January 28, 2004

- 68. December 19, 2003 PCT International Search Report issued in connection with PCT International Application No. PCT/US2001/012877, filed April 20, 2001, on behalf of The Trustees of Columbia University in the City of New York (Exhibit 67);
- 69. March 15, 2004 PCT International Search Report issued in connection with PCT International Application No. PCT/US2003/013164, filed April 30, 2003 on behalf of The Trustees of Columbia University in the City of New York (Exhibit 68);
- 70. U.S. Patent Application Publication No. US 2002-0128266 A1, published September 12, 2002, on behalf of Campbell et al.;
- 71. U.S. Patent Application Publication No. US 2002-0146681 A1, published October 10, 2002, on behalf of Rothblat;
- 72. Atger, V.M., et al. (1997) "Cyclodextrins as Catalysts for the Removal of Ccholesterol from Macrophage Foam Cells," J. Clin. Invest. 99: 773-780;
- 73. Braganza, D.M., et al. (2001) "New Insights into Atherosclerotic Plaque Rupture," Postgrad. Med. J. 77: 94-98;
- 74. Buton, X., et al. (1999) "Unique Cellular Events Ooccurring during the Initial Interaction of Macrophages with Matrix-retained or Methylated Aggregated Low Density Lipoprotein (LDL)," J. Biol. Chem. 274: 32112-32121;

Filed : January 28, 2004

- 75. Chang, et al. (1995) "Inhibition of Hypercholestemiainduced Atherosclerosis in the Nonhuman Primate by Probucol," Arterioscler. Thromb. Vasc. Biol. 15: 1631-1640;
- 76. Higgins, M.E., et al. (1999) "Niemann-pick C1 is a Late Endosome-resident Protein that Transiently Associates with Lysosomes and the Transgolgi Network," Molec. Genet. Metab. 68: 1-13;
- 77. Neufeld, E.B., et al. (1999) "The Niemann-pick Cl Protein Resides in a Vesicular Compartment Linked to Retrograde Transport of Multiple Lysosomal Cargo," J. Biol. Chem. 274: 9627-9635;
- 78. Rabbani, R., et al. (1999) "Strategies to Achieve Coronary Arterial Plaque Stabilization," Cardiovasc. Res. 41: 402-417;
- 79. Simons, K., et al. (2000) "How Cells Handle Cholesterol,"

 Science 290: 1721-1726;
- 80. Watari, H., et al. (2000) "NPC1-containing Compartment of Human Granulosa-lutein Ccells: A Role in the Intracellular Trafficking of Cholesterol Supporting Steriodogenesis," Exp. Cell Res. 255: 56-66;
- 81. Travis, A.J., et al. (2002) "The Role of Cholesterol Efflux in Regulating the Fertilization Potential of Mammalian Spermatozoa," J. Clin. Invest. 110: 731-736;
- 82. Smith, J.D., et al. (1996) "Cuclic AMP Induces Apolipoprotein E Binding Activity and Promotes Cholesterol

Filed : January 28, 2004

Page 13

Efflux from a Macrophage Cell Line to Apolipoprotein Acceptors, " J. Biol. Chem. 271: 30647-30655;

- 83. Kilsdonk, E.P., et al. (1995) "Cellular Cholesterol Efflux Mediated by Cyclodextrins," J. Biol. Chem. 270: 17250-17256;
- 84. Merriam-Webster Medline Plus online medical dictionary definition of "apolipoprotein," http://www.nlm.nih.gov/medlineplus/mplusdictionary.html, accessed online September 25, 2006, 1 page;
- 85. Carstea, E.D., et al. (1997) "Niemann-Pick C1 Disease Gene: Homology to Mediators of Cholesterol Homeostasis," Science 277: 228-231;
- 86. Mitchinson, M.J. et al. (1996) "Cell Death in Atherosclerotic Plaques," Curr. Opin. Lipidol. 7: 324-329;
- 87. Ball, R.Y., et al. (1995) "Evidence that the Death of Macrophage Foam Cells Contributes to the Lipid Core of Atheroma," Atherosclerosis 114: 45-54;
- 88. Bauriedel, G. et al. (1999) "Apoptosis and Its Regulation in Acute Coronary Syndrom Lesions," Circulation (Supp. I) 100: I-542, Abstract 2855;
- 89. Tabas, I. (1997) "Free Cholesterol-induced Cytotoxicity. A Possible Contributing Factor to Macrophage Foam Cell Necrosis in Advanced Atherosclerotic Lesions," Trends Cardiovasc. Med. 7: 256-263;

Filed : January 28, 2004

- 90. Tabas, I., et al. (1996) "Evidence that the Initial Upregulation of Phosphatidylcholine Biosynthesis in Free Cholesterol-loaded Macrophages is an Adaptive Response that Prevents Cholesterol-induced Cellular Necrosis. Proposed Role of an Eventual Failure of This Response in Foam Cell Necrosis in Advanced Atherosclerosis," J. Biol. Chem. 271: 22773-22781;
- 91. Liscum, L., et al. (1998) "Niemann-Pick Disease Type C,"

 Curr. Opin. Lipidol. 9: 131-135;
- 92. Loftus, S.K., et al. (1997) "Murine Model of Niemann-Pick C Disease: Mutation in A Cholesterol Homeostasis Gene,"

 Science 277: 232-235;
- 93. Shiratori, Y., et al. (1994) "Free Cholesterol Loading of Macrophages Stimulates Phosphatidylcholine Biosynthesis and Up-regulation of CTP: Phosphocholine Cytidylyltransferase,"

 J. Biol. Chem. 269: 11337-11348;
- 94. Aiello, R.J., et al. (2002) "Increased Atherosclerosis in Hyperlipidemic Mice with Inactivation of ABCA1 in Macrophages," Arterioscler. Thromb. Vasc. Biol. 22(4): 630-37;
- 95. Arakawa, R., et al. (2002) "Helical Apolipoproteins Stabilize ATP-binding Cassette Transporter A1 by Protecting it from Thiol Protease-mediated Degradation," J. Biol. Chem. 277: 22426-22429;
- 96. Attie, A.D., et al. (2001) "Pivotal Role of ABCA1 in Reverse Cholesterol Transport Influencing HDL Levels and

Filed : January 28, 2004

Page 15

Susceptibility to Atherosclerosis, " J. Lipid Res. 42: 1717-1726;

- 97. Berberian, P.A., et al. (1990) "Immunohistochemical Localization of Heat Shock Protein-70 in Normal-appearing and Atherosclerotic Specimens of Human Arteries," Am. J. Path. 136: 71-80;
- 98. Bretscher, M.S., et al. (1993) "Cholesterol and the Golgi Apparatus," Science 261: 1280-1281;
- 99. Chen W., et al. (2001) "Preferential ATP-binding Cassette Transporter A1-mediated Cholesterol Efflux from Late Endosomes/Lysosomes," J. Biol. Chem. 276: 43564-43569;
- 100. Christian, A.E. et al. (1997) "Use of Cyclodextrins for Manipulating Cellular Cholesterol Content," J. Lipid Res. 38: 2264-2272;
- 101. Costet, P. et al. (2000) "Sterol-dependent Transactivation of the ABC1 Promoter by the Liver X Receptor/retinoid X Receptor," J. Biol. Chem. 275: 28240-28245;
- 102. Fazio, S., et al. (2001) "Increased Atherosclerosis in LDL Receptor-null Mice Lacking ACAT1 in Macrophages," J. Clin. Invest. 107: 163-71;
- 103. Feng, B., et al. (2002) "ABCA1-mediated Cholesterol Efflux
 is Defective in Free Cholesterol-loaded Macrophages.
 Mechanism involves Enhanced ABCA1 Degradation in a Process
 Requiring Full NPC1 Activity," J. Biol. Chem. 277: 4327143280;

Filed : January 28, 2004

- 104. Haghpassand M., et al. (2001) "Monocyte/macrophage Expression of ABCA1 has Minimal Contribution to Plasma HDL Levels," J. Clin. Invest. 108: 1315-1320;
- 105. Joyce C.W., et al., (2002) "The ATP Binding Cassette Transporter A1 (ABCA1) Modulates the Development of Aortic Atherosclerosis in C57BL/6 and ApoE-knockout Mice," Proc. Natl. Acad. Sci. U. S. A. 99: 407-412;
- 106. Kellner-Weibel, G., et al. (1999) "Cytotoxic Cholesterol is Generated by the Hydrolysis of Cytoplasmic Cholesterylester and Transported to the Plasma Membrane," Atherosclerosis 146: 309-319;
- 107. Kellner-Weibel, G., et al. (1998) "Effects of Intracellular Free Cholesterol Accumulation on Macrophage Viability: A Model for Foam Cell Death," Arterioscler. Thromb. Vasc. Biol. 18: 423-431;
- 108. Khan, N., et al. (2003) "Plasma Membrane Cholesterol: A Possible Barrier to Intracellular Oxygen in Normal and Mutant CHO Cells Defective in Cholesterol Metabolism,"

 Biochemistry 42: 23-29;
- 109. Kolodgie, F.D., et al. (2000) "Localization of Apoptotic Macrophages at the Site of Plaque Rupture in Sudden Coronary Death," Am. J. Pathol. 157: 1259-1268;
- 110. Kruth, H.S., et al., (1984) "Histochemical Detection and Differentiation of Free and Esterified Cholesterol in Swine

Filed : January 28, 2004

Page 17

Atherosclerosis Using Filipin, " Exp. Mol. Pathol. 40: 288-294;

- 111. Lange, Y., et al. (1997) "Quantitation of the Pool of
 Cholesterol Associated with Acyl-CoA:cholesterol
 Acyltransferase in Human Fibroblasts," J. Biol. Chem. 272:
 13103-13108;
- 112. Lange, Y., et al. (2000) "Cholesterol Movement in Niemann-Pick Type C Cells and in Cells Treated with Amphiphiles,"

 J. Biol. Chem. 275: 17468-17475;
- 113. Lange, Y., et al. (1997) "The Fate of Cholesterol Exiting Lysosomes," J. Biol. Chem. 272: 17018-17022;
- 114. Lange, Y. (1992) "Tracking Cell Cholesterol With Cholesterol Oxidase," J. Lipid Res. 33: 315-321;
- 115. Leventhal A.R.; et al. (2001) "Acid Sphingomyelinase-Deficient Macrophages have Defective Cholesterol Trafficking and Eefflux," J. Biol. Chem. 276: 44976-44983;
- 116. Libby, P., et al. (1993) "The Role of Macrophages in Atherogenesis," Curr. Opin. Lipidol. 4: 355-363;
- 117. Liscum, L., et al. (1998) "Niemann-Pick disease type C,"

 Curr. Opin. Lipidol. 9: 131-135;
- 118. Loftus, S.K., et al. (1997) "Murine Model of Niemann-Pick C
 Disease: Mutation in a Cholesterol Homeostasis Gene,"
 Science 277: 232-235;

Filed : January 28, 2004

- 119. Lundberg, B. (1985) "Chemical Composition and Physical State of Lipid Deposits in Atherosclerosis,"

 Atherosclerosis 56: 93-110;
- 120. Mallat, Z., et al. (1999) "Shed Membrane Microparticles with Procoagulant Potential in Human Atherosclerotic Plaques: A Role for Apoptosis in Plaque Thrombogenicity," Circulation 99: 348-353;
- 121. Marathe S., et al. (1998) "Human Vascular Endothelial cells are a Rich and Regulatable Source of Secretory Sphingomyelinase. Implications for Early Atherogenesis and Ceramide-mediated Cell Signaling," J. Biol. Chem. 273: 4081-4088;
- 122. Mitchinson, M.J., et al. (1996) "Cell Death in Atherosclerotic Plaques," Curr. Opin. Lipidol. 7: 324-329;
- 123. Rapp, J.H., et al. (1983) "Lipids of Human Atherosclerotic Plaques and Xanthomas: Clues to the Mechanism of Plaque Progression," J. Lipid Res. 24: 1329-1335;
- 124. Ross, R. (1995) "Cell biology of atherosclerosis," Annu. Rev. Physiol. 57: 791-804;
- 125. Schissel, S.L., et al. (1998) "Secretory Sphingomyelinase, a Product of the Acid Sphingomyelinase Gene, can Hydrolyze Atherogenic Lipoproteins at Neutral pH. Implications for Atherosclerotic Lesion Development," J. Biol. Chem. 273: 2738-2746;

Filed : January 28, 2004

- 126. Sparrow, S.M., et al. (1999) "U18666A Inhibits Intracellular Cholesterol Transport and Neurotransmitter Release in Human Neuroblastoma Cells," Neurochem. Res. 24: 69-77;
- 127. Tabas, I. (2000) "Cholesterol and Phospholipid Metabolism in Macrophages," *Biochim. Biophys. Acta* 1529: 164-174;
- 128. Tabas, I. (2002) "Consequences of Cellular Cholesterol Accumulation: Basic Concepts and Physiological Implications," J. Clin. Invest. 110: 905-911;
- 129. Tall, A.R. (1998) "An Overview of Reverse Cholesterol Transport," Eur. Heart J. A31-A35;
- 130. Trogan, E., et al. (2002) "Laser Ccapture Microdissection Analysis of Gene Expression in Macrophages from Atherosclerotic Lesions of Apolipoprotein E-deficient Mice," Proc. Natl. Acad. Sci. U.S.A. 99: 2234-2239;
- 131. Underwood, K.W., et al. (1998) "Evidence for a Cholesterol Transport Pathway from Lysosomes to Endoplasmic Reticulum that is Independent of the Plasma Membrane," J. Biol. Chem. 273: 4266-4274;
- 132. Underwood, K.W., et al. (1996) "Quantitative Analysis of Hydrophobic Amine Inhibition of Intracellular Cholesterol Transport," J. Lipid Res. 37: 1556-1568;
- 133. Vaisman, B.L., et al. (2001) "ABCA1 Overexpression Leads to Hyperalphalipoproteinemia and Increased Biliary Cholesterol

Filed : January 28, 2004

Page 20

Excretion in Transgenic Mice, " J. Clin. Invest. 108: 303-309;

- 134. van Eck, M., et al. (2002) "Leukocyte ABCA1 Controls Susceptibility to Atherosclerosis and Macrophage Recruitment into Tissues," *Proc. Natl. Acad. Sci. U.S.A.* 99: 6298-6303, E-published 2002 Apr 23;
- 135. Wang, Y., et al. (2002) "Unsaturated Fatty Acids Inhibit Cholesterol Efflux From Macrophages by Increasing Degradation of ATP-binding Cassette Transporter A1," J. Biol. Chem. 277: 5692-5697;
- 136. Williams, K.J., et al. (1995) "A Reexamination of the NRMP Matching Algorithm. National Resident Matching Program,"

 Arterioscler. Thromb. Vasc. Biol. 15: 551-561;
- 137. Yancey, P.G., et al. (1996) "Cellular Cholesterol Efflux Mediated by Cyclodextrins. Demonstration of Kinetic Pools and Mechanism of Efflux," J. Biol. Chem. 271: 16026-16034;
- 138. Yao, P.M., et al. (2000) "Free Cholesterol Loading of Macrophages Induces Apoptosis Involving the Fas Pathway,"

 J. Biol. Chem. 275: 23807-23813;
- 139. Yao, P.M., et al. (2001) "Free Cholesterol Loading of Macrophages is Associated with Widespread Mitochondrial Dysfunction and Activation of the Mitochondrial Apoptosis Pathway," J. Biol. Chem. 276: 42468-42476;
- 140. Yeagle, P.L. (1991) "Modulation of Membrane Function by Cholesterol," *Biochimie* 73: 1303-1310;

Filed : January 28, 2004

Page 21

- 141. Zhang, D., et al. (2000) "Macrophages Deficient in CTP: Phosphocholine Ccytidylyltransferase-alpha are Viable Under Normal Culture Conditions but are Highly Susceptible to Free Cholesterol-induced Death. Molecular Genetic Evidence That the Induction of Phosphatidylcholine Biosynthesis in Free Cholesterol-loaded Macrophages is an Adaptive Response," J. Biol. Chem. 275: 35368-35376; and
- 142. Kapczinski, F., et al. (2003) "Antidepressants for Generalized Anxiety Disorder," Cochrane Databse Syst. Rev. 2003:CD003592, abstract.

The subject application is a continuation-in-part of and claims benefit of U.S. Serial No. 09/553,927, filed April 21, 2000, and U.S. Serial No. 10/426,415, filed April 30, 2003, which claims priority of U.S. Provisional Application No. 60/376,984, filed April 30, 2002, and U.S. Provisional Application No. 60/494,721, filed August 11, 2003.

A copy of U.S. Serial No. 09/553,927 is attached hereto as **Exhibit 1**. An Office Action was issued on May 7, 2001 in connection with U.S. Serial No. 09/553,927. A copy is attached hereto as **Exhibit 60**. Above-listed references 72-80 were cited in the May 7, 2001 Office Action. Accordingly, under 37 C.F.R. \$1.98(d) copies of these references are not required to be provided to the United States Patent and Trademark Office, since they were previously cited by the United States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120. A Final Office Action was issued on March 8, 2002 in connection with U.S. Serial No. 09/553,927. A copy is attached hereto as **Exhibit 61**. An Advisory

Filed : January 28, 2004

Page 22

Action was issued on September 9, 2002 in connection with U.S. Serial No. 09/553,927. A copy is attached hereto as **Exhibit 62**. An Office Action was issued on July 29, 2003 in connection with U.S. Serial No. 09/553,927. A copy is attached hereto as **Exhibit** 63.

U.S. Serial No. 10/426,415 is a published application listed above as reference 2. Accordingly, pursuant to 37 C.F.R. §1.98(a)(ii) a copy of this application is not required to be provided to the United States Patent and Trademark Office. An Office Action was issued on September 21, 2005 in connection with U.S. Serial No. 10/426,415. A copy is attached hereto as Exhibit 64. Above-listed reference 149 was cited in the September 21, 2005 Office Action. An Office Action was issued on March 24, 2006 in connection with U.S. Serial No. 10/426,415. A copy is attached hereto as Exhibit 65. Above-listed references 81-83 were cited in the March 24, 2006 Office Action. A Final Office Action was issued on October 4, 2006 in connection with U.S. Serial No. 10/426,415. A copy is attached hereto as Exhibit 66. Above-listed reference 84 was cited in the October 4, 2006 Final Office Action. Accordingly, under 37 C.F.R. §1.98(d) copies of references 81-84 and 149 are not required to be provided to the United States Patent and Trademark Office, since they were previously cited by the United States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120.

Above-listed references 85-93 were submitted to and considered by the United States Patent and Trademark Office in an Information Disclosure Statement filed on April 16, 2001 in connection with U.S. Serial No. 09/553,927, filed April 21, 2000. Accordingly, under 37 C.F.R. §1.98(d) copies of these references are not required to be provided to the United States Patent and Trademark

Filed : January 28, 2004

Page 23

Office, since they were previously submitted to or cited by the United States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120.

Above-listed references 94-148 were submitted to and considered by the United States Patent and Trademark Office in an Information Disclosure Statement filed on September 4, 2003 in connection with U.S. Serial No. 10/426,415, filed April 30, 2003. Accordingly, under 37 C.F.R. §1.98(d) copies of these references are not required to be provided to the United States Patent and Trademark Office, since they were previously submitted to or cited by the United States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120.

PCT International Application No. PCT/US2001/012877, filed April 20, 2001, is a related foreign application, which also claims priority of U.S. Serial No. 09/553,927, filed April 21, 2000. A copy of PCT International Application No. PCT/US2001/012877 is attached hereto as **Exhibit 2**.

An International Search Report was issued on December 19, 2003 in connection with PCT International Application No. PCT/US2001/012877, filed April 20, 2001. A copy of the Search Report is attached hereto as **Exhibit 67**. Above-listed reference 35 (copy attached hereto as **Exhibit 34**) was cited in the Search Report.

An International Preliminary Examination Report was issued on December 22, 2006 in connection with PCT International Application No. PCT/US2001/012877, filed April 20, 2001. A copy of the Report is attached hereto as **Exhibit 4**.

Filed : January 28, 2004

Page 24

PCT International Application No. PCT/US2003/013164, filed April 30, 2003, is a related foreign application, which also claims priority of U.S. Provisional Application No. 60/376,984, filed April 30, 2002. A copy of PCT International Application No. PCT/US2003/013164 is attached hereto as **Exhibit 3**.

An International Search Report was issued on March 15, 2004 in connection with PCT International Application No. PCT/US2003/013164, filed April 30, 2003. A copy of the Search Report is attached hereto as Exhibit 68. Above-listed references 70 and 71 were cited in the Search Report. These references are published U.S. applications. Accordingly, pursuant to 37 C.F.R. §1.98(a)(ii) copies of these applications are not required to be provided to the United States Patent and Trademark Office.

Applicant requests that the Examiner review the documents listed above and make them of record in the subject application.

Pursuant to 37 C.F.R. 1.97(c)(2), the required fee for filing this Information Disclosure Statement is ONE HUNDRED AND EIGHTY DOLLARS (\$180.00) and a check for this amount is enclosed.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other that the enclosed \$180.00 fee, is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any additional fee is required,

Applicant

: Ira Tabas

Serial No.

: 10/767,749

Filed

: January 28, 2004

Page 25

authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

John P. White

Reg. No. 28,678

John P White

Registration No. 28,678
Attorney for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036

(212) 278-0400

1449 Substitute **U.S. Department of Commerce**

Patent and Trademark Office

Application Number	10/797,749
Filing Date	January 28, 2004
First Named Inventor	Ira Tabas
Art Unit	1647
Examiner Name	B.E. Bunner
Attorney Docket No.	0575/60921-A/JPW/MVM

DISCLOSURE STATEMENT (Use several sheets if necessary)

U.S. PATENT DOCUMENTS				
Examiner Initials	Cite No.1	Document Number Number-Kind Code ^{2 (If known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	1	US 09/553,927	04-21-2000	Tabas et al.
		US 2003-0235878 A1		Tabas et al.
	70	US 2002-0128266 A1	09-12-2002	Campbell et al.
	71	US 2002-0146681 A1	10-10-2002	Rothblat
	_			
				·
	-			

FORFICN PATENT DOCUMENTS

	FOREIGN PATENT DUCUMENTS						
Examiner Initials*	No.1	Country Code ³ Number Kind Code ^{5 (If known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶		
		WO 2001/080715 A3	11-01-2001	The Trustees of Columbia University in the City of New York			
	4	WO 2003/092467 A3	11-13-2003	The Trustees of Columbia University in the City of New York			
EXAMINER SIGNATURI			DATE CONSIDERED				

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English Language Translation is attached.

> Applicants: Ira Tabas U.S. Serial No.: 10/767,749 Filed: January 28, 2004

Exhibit A

Form PTO-1449 Substitute

U.S. Department of Commerce Patent and Trademark Office

Application Number 10/797,749 Filing Date January 28, 2004 First Named Inventor Ira Tabas Art Unit 1647

INFORMATION DISCLOSURE CITATION

(Use severa	(Use several sheets if necessary)			B.E. Bunner	
	Attorney Docket No. 0575/60921-A/JPV				
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) publisher, city and/or country where	date, page(s), volume-issi published.	ne number(s),	
	5	December 22, 2006 International Pr Report issued in connection wit Application No. PCT/US2001/12877, f	eliminary Exa h PCT Inter iled April 20	national , 2001	
	6	Aikawa, K., et al. (1994) "Structur of Lysosomal Cholesterol Transpor Various Steriods," <i>Biochim. Biophys</i>	t in Macropl . <i>Acta</i> 1213:	nages by 127-134	
•	7	Arends, M.J., et al. (1991) "Apopt Roles in Pathology," <i>Int. Rev. Expe</i>	r. Pathol. 32:	223-254	
	8	Basu, S.K., et al. (1976) "Degradat Density Lipoprotein and Regulat Metabolism in Homozygous Familial Fibroblasts," <i>Proc. Natl. Acad. Sci</i>	ion of Cho Hypercholest . U.S.A. 73: 3	lesterol erolemia 178-3182	
·	9	Bertolotti, A., et al. (2000) "Dyname and ER Stress Transducers in Response," <i>Nat. Cell Biol</i> . 2: 326-3	nic Interaction the Unfolded 32	n of BiP -protein	
	10	Bjorkhem, I., et al. (1994) "Atherone 27-Hydroxylase: Evidence for a Roselimination of Cholesterol From Human Natl. Acad. Sci. U.S.A. 91: 8592-85	le of This En an Macrophages	nzvme in	
	11	Brown, M.S., et al. (1983) "Lipoprot Macrophage: Implications for Chole Atherosclerosis ¹ ," <i>Annu. Rev. Bioch</i> e	ein Metabolis sterol Depos	ition in	
	12	Brown, M.S., et al. (1997) "The SREE of Cholesterol Metabolism by Protec Bound Transcription Factor," <i>Cell</i> 8	BP Pathway: Re olysis of a M	qulation	
	13	Calfon, M., et al. (2002) "IRE1 Reticulum Load to Secretory Capaci XBP-1 mRNA," Nature 415: 92-96	Couples End ty by Process	sing the	
	14	Chang, MK., et al. (1999) "Monoclor Oxidized Low-density Lipoprotein Bi and Inhibit Their Phagocytosis by Evidence that Oxidation-specific Macrophage Recognition," <i>Proc. Natl.</i> 6353-6358	nd to Apoptot Elicited Macro Epitopes Acad. Sci. U.	ic Cells ophages: Mediate S.A. 96:	
	15	Devlin, C., et al. (2002) "Genetic Receptor Antagonist in Mice Affec Level and Foam Cell Lesion Size," <i>P U.S.A</i> . 99: 6280-6285	t Plasma Cho	lesterol	

EXAMINER SIGNATURE DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Page 3 of 13

Form PTO-1449 Substitute U.S. Department of Commerce Patent and Trademark Office

Application Number 10/797,749 Filing Date January 28, 2004 First Named Inventor Ira Tabas Art Unit 1647 Examiner Name B.E. Bunner

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

(Use several sheets if necessary)		Examiner Name	B.E. Bunner	
		Attorney Docket No.	0575/60921-A/JPW/MVM	
	NON PATENT LITERATURE DOC	UMENTS		
Examiner Cite Initials No. No. I	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) of publisher, city and/or country where	date, page(s), volume-issu published.	ne number(s),	
16	Feng, B., et al. (2003) "The Endopla Site of Cholesterol-induced Cytotox: Nat. Cell Biol. 5: 781-792	asmic Reticulu icity in Macro	phages,"	
17	Feng, B., et al. (2003) "Niemann-I Confers Resistance to Lesional Neo Apoptosis in Murine Atherosclerosi 10428	crosis and Ma s," <i>PNAS</i> 100	crophage : 10423-	
18	Fuster, V., et al. (1992) "The Pat Artery Disease and the Acute Coronar Two Parts)," <i>N. Engl. J. Med.</i> 326:	y Syndromes: (242-250	Coronary First of	
19	Graham, J.M., et al. (1970) Mitochondria Enriched <i>in vitro</i> with <i>Biochem</i> . 12: 58-66	Cholesterol,"	Eur. J.	
20	Green, D.R. (1998) "Apoptotic Pathways: The Roads to Ruin," Cell 94: 695-698			
21	Guyton, J.R., et al. (1996) "Develop Core in Human Atherosclerosis," <i>A</i> Vase. Biol. 16: 4-11	Arterioscler.	Thromb.	
22	Harding, H.P., et al. (1999) "Pro Folding are Coupled by an Endoplasm Kinase," <i>Nature</i> 397: 271-274 Harding, H.P., et al. (2000) " <i>Pe</i>	ic-reticulum-	resident	
23	Translational Regulation and Cell Unfolded Protein Response," <i>Mol. Ce</i>	Survival dur 11 5: 897-904	ring the	
24	Harding, H.P., et al. (2000) "R Initiation Controls Stress-Induced Mammalian Cells," <i>Mol. Cell</i> 6: 1099	egulated Tra Gene Expres -1108	nslation sion in	
25 <u> </u>	Harding, H.P., et al. (2001) "Di Exocrine Pancreatic Dysfunction in F Role for Translational Control Survival," <i>Mol. Cell</i> 7: 1153-1163	Perk-I- Mice R in Secretor	eveals a cy Cell	
26	Kockx, M.M., et al. (1998) "RNA Sy Interferes with DNA <i>in Situ</i> End Lab to Detect Apoptosis," <i>Am. J. Pathol</i>	eling Techniq . 152: 885-88	ues Used 8	
27		the Atheros alitative A 8: 1519-1522	clerotic spects,"	

EXAMINER SIGNATURE DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Page 4 of 13

Form PTO-1449 Substitute

U.S. Department of Commerce Patent and Trademark Office

Application Number Filing Date

10/797,749 January 28, 2004

B.E. Bunner

First Named Inventor Ira Tabas Art Unit 1647

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

SIGNATURE

Examiner Name Attorney Docket No. 0575/60921-A/JPW/MVM

		Attorney Docket No. 0575/60921-A/JPW	V/MVM
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	28	Kruth, H.S. (1985) "Subendothelial Accumulation of Unesterified Cholesterol: An Early Event in Atherosclerotic Lesion Development," Atherosclerosis 57: 337-341	
	29	Kruth, H.S., et al. (1986) "Type C Niemann-pick Disease: Abnormal Metabolism of Low Density Lipoprotein in Homozygous and Heterozygous Fibroblast*," J. Biol. Chem. 261: 16769-16774	
	30	Lemasters, J. J. (1999) "Mechanisms of Hepatic Toxicity V. Necrapoptosis and the Mitochondrial Permeability Transition: Shared Pathways to Necrosis and Apoptosis*," Am. J. Physiol. 276: G1-G6	
	31	Liscum, L., et al. (1992) "Intracellular Cholesterol Transport," <i>J. Lipid Res.</i> 33: 1239-1254	
	32	Lopes-Virella, M.F., et al. (1992) "Immune Mechanisms of Atherosclerosis in Diabetes Mellitus," <i>Diabetes</i> 41 (Suppl. 2): 86-91	
	33	Majno, G., et al. (1995) "Apoptosis, Oncosis, and Necrosis: An Overview of Cell Death," <i>Am. J. Pathol</i> . 146: 3-15	
	34	Matsuda, K. (1994) "ACAT Inhibitors as Antiatherosclerotic Agents: Compounds and Mechanisms," <i>Med. Res. Rev.</i> 14: 271-305	
	35	Maxfield, F.R. (2002) "Intracellular Cholesterol Transport," <i>J. Clin. Invest</i> . 110: 891-898	
	36	McCullough, K.D., et al. (2001) "Gadd153 Sensitizes Cells to Endoplasmic Reticulum Stress by Down-Regulating Bc12 and Perturbing the Cellular Redox State," Mol. Cell Biol. 21: 1249-1259	
	37	Nakagawa, T., et al. (2000) "Caspase-12 Mediates Endoplasmic-reticulum-specific Apoptosis and Cytotoxicity by Amyloid- β ," Nature 403: 98-103	
	38	Nakashima, Y., et al. (1994) "ApoE-Deficient Mice Develop Lesions of All Phases of Atherosclerosis Throughout the Arterial Tree," <i>Arterioscler. Thromb</i> . 14: 133-140	
	39	Nishitoh, H., et al. (2002) "ASK1 is Essential for Endoplasmic Reticulum Stress-induced Neuronal Cell Death Triggered by Expanded Polyglutamine Repeats," <i>Genes Dev</i> . 16: 1345-1355	
EXAMINER		DATE CONSIDERED	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached. Form PTO-1449 Substitute

U.S. Department of Commerce Patent and Trademark Office Application Number 10/797,749

Filing Date January 28, 2004

First Named Inventor Ira Tabas

Art Unit 1647

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

SIGNATURE

First Named Inventor Ira Tabas

Art Unit 1647

Examiner Name B.E. Bunner

Attorney Docket No. 0575/60921-A/JPW/MVM

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	40	Oyadomari, S., et al. (2002) "Targeted Disruption of the Chop Gene Delays Endoplasmic Reticulum Stress-mediated Diabetes," J. Clin. Invest. 109: 525-532	
	41	Papahadjopoulos, D. (1974) "Cholesterol and Cell Membrane Function: A Hypothesis Concerning the Etiology of Artherosclerosis," J. Theor. Biol. 43: 329-337	
	42	Patil, C., et al. (2001) "Intracellular Signaling from the Endoplasmic Reticulum to the Nucleus: The Unfolded Protein Response in Yeast and Mammals," Curr. Opin. Cell Biol. 13: 349-356	
	43	Pentchev, P.G., et al. (1984) "A Genetic Storage Disorder in BALB/C Mice with a Metabolic Block in Esterification of Exogenous Cholesterol*," J. Biol. Chem. 259: 5784-5791	· · · · · · · · · · · · · · · · · · ·
	44	Pentchev, P.G., et al. (1997) "Biological Implications of the Niemann-Pick C Mutation," Sub-Cell. Biochem. 28: 437- 451	
	45	Reddick, R.L., et al. (1994) "Atherosclerosis in Mice Lacking Apo E: Evaluation of Lesional Development and Progression," <i>Arterioscler. Thromb</i> . 14: 141-147	
	46	Ross, A.C., et al. (1984) "Selective Inhibition of Acyl Coenzyme A: Cholesterol Acyltransferase by Compound 58-035*," J. Biol. Chem. 259: 815-819	
	47	Ross, D.D., et al. (1989) "Estimation of Cell Survival by Flow Cytometric Quantification of Fluorescein Diacetate/Propidium Iodide Viable Cell Number ¹ ," <i>Cancer Res</i> . 49: 3776-3782	
	48	Small, D.M., et al. (1984) "Physicochemical and Histological Changes in the Arterial Wall of Nonhuman Primates during Progression and Regression of Atherosclerosis," J. Clin. Invest. 73: 1590-1605	4
	49	Smith, J. D., et al. (1995) "Decreased Atherosclerosis In Mice Deficient In Both Macrophage Colony-stimulating Factor (op) and Apoliprotein E," Proc. Natl. Acad. Sci. U.S.A. 92: 8264-8268	
	50	Tabas, I., et al. (1988) "Rabbit Liver Microsomal ACAT: Smooth ER Enzyme Associated With A Lipid ACAT Inhibitor," Arteriosclerosis 8: 559A	
	51	Tang, W.A., et al. (1999) "Macrophage-targeted CTP: Phosphocholine Cytidylyltransferase (1-314) Transgenic Mice," <i>Biochim. Biophys. Acta</i> 1437: 301-316	
EXAMINER	1	DATE CONSIDERED	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 Substitute
U.S. Department of Commerce
Patent and Trademark Office

Application Number 10/797,749

Filing Date January 28, 2004

First Named Inventor Ira Tabas

Art Unit 1647

Examiner Name B.E. Bunner

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

EXAMINER

SIGNATURE

(Ose severa	ii siicets	Examiner Name B.E. Bunner	
		Attorney Docket No. 0575/60921-A/JPV	W/MVM
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	52	Travers, K.J., et al. (2000) "Functional and Genomic Analyses Reveal an Essential Coordination between the Unfolded Protein Response and ER-Associated Degradation," Cell 101: 249-258	
	53	Treiman, M. (2002) "Regulation of the Endoplasmic Reticulum Calcium Storage During the Unfolded Protein Response-Significance in Tissue Ischemia?" <i>Trends Cardiovasc. Med.</i> 12: 57-62	
	54	Kinases IRE1," Science 287: 664-666	
	55	Wang, X.Z., et al. (1996) "Stress-Induced Phosphorylation and Activation of the Transcription Factor CHOP (GADD153) by p38 MAP Kinase," <i>Science</i> 272: 1347-1349	
	56	Warner, G.J., et al. (1995) "Cell Toxicity Induced by Inhibition of Acyl Coenzyme A: Cholesterol Acyltransferase and Accumulation of Unesterified Cholesterol*," J. Biol. Chem. 270: 5772-5778	
	57	Yoshida, H. (2001) "XBP1 mRNA is Induced by ATF6 and Spliced by IRE1 in Response to ER Stress to Produce a Highly Active Transcription Factor," <i>Cell</i> 107: 881-891	
	58	Zhang, C., et al. (1998) "A Cell Surface Receptor Defined by a mAb Mediates A Unique Type of Cell Death Similar to Oncosis," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 95: 6290-6295	
	59	Zhang, P., et al. (2002) "The PERK Euraryotic Initiation Factor 2α Kinase Is Required for the Development of Sketetal System, Postnatal Growth, and the Function and Viability of the Pancreas," Mol. Cell Biol. 22: 3864-3874	N
	60	Zinszner, H., et al. (1998) "CHOP is Implicated in Programmed Cell Death in Response to Impaired Function of the Endoplasmic Reticulum," <i>Genes Dev.</i> 12: 982-995	
		May 7, 2001 Office Action issued by the United States Patent and Trademark Office in connection with U.S. Application Serial No. 09/553,927	
	62	March 8, 2002 Office Action issued by the United States Patent and Trademark Office in connection with U.S. Application Serial No. 09/553,927	·
	63	September 9, 2002 Advisory Action issued by the United States Patent and Trademark Office in connection with U.S. Application Serial No. 09/553,927	
	_		

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

DATE CONSIDERED

Form P7	ГО-144	9 Substitute U.	S. Department of Commerce	Application Number	Page 7 of 1 10/797,749
			tent and Trademark Office	Filing Date	January 28, 2004
				First Named Inventor	
INFORM	MATI(ON DISCLOSURE C	ITATION	Art Unit	1647
		s if necessary)		Examiner Name	B.E. Bunner
		• • • •			0575/60921-A/JPW/MVM
		NON PA	ATENT LITERATURE DOC		
Examiner	Cite			 	
Initials	No.1	item (book, magazine, jo	or (in CAPITAL LETTERS), title of the ournal, serial, symposium, catalog, etc.) publisher, city and/or country where	date, page(s), volume-issu published.	ie number(s),
	64	Patent and Transplication Se	Office Action issued rademark Office in crial No. 09/553,927	by the Unite connection wi	th U.S.
	65	September 21, States Patent a Application Se	2005 Office Action and Trademark Office i rial No. 10/426,415	n connection w	vith U.S.
	66	Patent and Tr Application Se	Office Action issued rademark Office in rial No. 10/426,415	connection wi	th U.S.
	67	Patent and Tr Application Se	6 Office Action issued cademark Office in c rial No. 10/426,415	connection wi	th U.S.
	68	connection wi PCT/US2001/012 WO/2001/080715	2003 PCT Internation th PCT Internation 877, filed April 20, A3, published November Columbia University	al Applicati 2001, publica r 1, 2001 on b	ion No. tion No. ehalf of
	69	connection wi PCT/US2003/013:	PCT International Se th PCT Internation 164, filed April 30, lumbia University in	al Applicati 2003 on behal	on No.
	72	Atger, V.M., et the removal of <i>Clin. Invest.</i>	al. (1997) "Cyclodext cholesterol from macro 99: 773-780	rins as catal	vsts for
	73	98	plaque rupture," Posi		77: 94-
	74	during the init retained or met (LDL)," J. Bio.	l. (1999) "Unique cellial interaction of machylated aggregated lol. Chem. 274: 32112-32	crophages with w density lipo 2121	matrix- oprotein
		induced athero probucol," Arte	(1995) "Inhibition osclerosis in the r erioscler Thromb. Vasc	nonhuman prim . <i>Biol</i> . 15: 16	nate by 531-1640
		Higgins, M.E.,	et al. (1999) "Niema nt protein that transi	nn-pick C1 is	a late

EXAMINER SIGNATURE DATE CONSIDERED

Metab. 68: 1-13

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

lysosomes and the transgolgi network," Molec. Genet.

Page 8 of 13

Form PTO-1449 Substitute U.S. Department of Commerce Application Number 10/797,749 Filing Date January 28, 2004 Patent and Trademark Office First Named Inventor Ira Tabas INFORMATION DISCLOSURE CITATION Art Unit 1647 (Use several sheets if necessary) B.E. Bunner Examiner Name Attorney Docket No. 0575/60921-A/JPW/MVM NON PATENT LITERATURE DOCUMENTS Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner T^2 No.1 Initials* item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Neufeld, E.B., et al. (1999) "The Niemann-pick Cl protein 77 resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo," J. Biol. Chem. 274: 9627-9635 Rabbani, R., et al. (1999) "Strategies to achieve coronary arterial plaque stabilization," Cardiovasc. Res. 41: 402-417 Simons, K., et al. (2000) "How cells handle cholesterol," 79 Science 290: 1721-1726 Watari, H., et al. (2000) "NPC1-containing compartment of human granulosa-lutein cells: a role in the intracellular 80 trafficking of cholesterol supporting steriodogenesis," Exp. Cell Res. 255: 56-66 Travis, A.J., et al. (2002) "The role of cholesterol efflux in regulating the fertilization potential of 81 mammalian spermatozoa," J. Clin. Invest. 110: 731-736 J.D., et al. (1996) "Cuclic AMP apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors, " J. Biol. Chem. 271: 30647-30655 Kilsdonk, E.P., et al. (1995) "Cellular cholesterol efflux mediated by cyclodextrins," J. Biol. Chem. 270: 17250-17256 Merriam-Webster Medline Plus online medical dictionary definition "apolipoprotein," http://www.nlm.nih.gov/medlineplus/mplusdictionary.html, accessed online September 25, 2006, 1 page Carstea, E.D., et al. (1997) "Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis," 85 Science 277: 228-231 Mitchinson, M.J., et al. (1996) "Hardwick, and M.R. Bennett. Cell death in atherosclerotic plaques, " Curr. Opin. Lipidol. 7: 324-329 Ball, R.Y., et al. (1995) "Evidence that the death of 87 macrophage foam cells contributes to the lipid core of atheroma," Atherosclerosis 114: 45-54 Bauriedel, G. et al. (1999) "Apoptosis and Its Regulation 88 in Acute Coronary Syndrom Lesions," Circulation (Supp. I) 100: I-542, Abstract 2855 EXAMINER DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

SIGNATURE

Form PT	O-144	9 Substitute	U.S. Department of Commerce	Application Number	10/797,749
				Filing Date	January 28, 2004
				First Named Inventor	Ira Tabas
INFORM	IATIC	N DISCLOSU	RE CITATION	Art Unit	1647
(Use severa	l sheets	if necessary)			B.E. Bunner
				Attorney Docket No.	0575/60921-A/JPW/MVM
		NO	ON PATENT LITERATURE DOC	UMENTS	
Examiner Initials	Cite No.1	Include name of th	ne author (in CAPITAL LETTERS), title of the zine, journal, serial, symposium, catalog, etc.) publisher, city and/or country where	date, page(s), volume-issi	ite), title of the ne number(s),
	89	possible onecrosis i Cardiovasc	(1997) "Free cholesterol-i contributing factor to .n advanced atherosclero . <i>Med</i> . 7: 256-263	nduced cytotom macrophage for tic lesions,	oam cell ' <i>Trends</i>
	90	regulation cholestero that preve Proposed re foam cell r	et al. (1996) "Evidence of phosphatidylcholine l-loaded macrophages is ents cholesterol-induced ole of an eventual failur necrosis in advanced ather 22773-22781	biosynthesis an adaptive d cellular n ce of this res	in free response ecrosis. ponse in
	91	Curr. Opin	et al. (1998) "Niemann- . <i>Lipidol</i> . 9: 131-135		
	92	C disease: Science 27		ol homeostasi	s gene,"
		macrophages and u cytidylylti	Y., et al. (1994) "Free of stimulates phosphatidy of cansferase," J. Biol. Ch	lcholine bios CTP:phosph mem. 269: 1133	ynthesis ocholine 7-11348
	94	hyperlipide macrophages 630-37	J. et al. (2002) "Increasemic mice with inactives," Arterioscler. Thromb	vation of A	BCA1 in
	95	protecting J. Biol. Cl	ATP-binding cassette it from thiol protease-mnem. 277: 22426-22429	transporter ediated degra	dation,"
	96	reverse cho susceptibil 1717–1726	., et al. (2001) "Pivot plesterol transport influ lity to atherosclerosis,	encing HDL le	vels and Res. 42:
	97	and atheros <i>Path</i> . 136:		70 in normal-a man arteries,	ppearing " Am. J.
	98	Bretscher, apparatus,"	M.S., et al. (1993) "Chol ' <i>Science</i> 261: 1280-1281	esterol and t	he Golgi
EXAMINER	t_		DATE CONSIDERED		

Form PTO-1449 Substitute

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'Applicant is to place a checkmark here if English language Translation is attached.

Form P1	·O-144	9 Substitute	U.S. Department of Commerce	Application Number	Page 10 (of 1
			Patent and Trademark Office	Filing Date	January 28, 200)4
				First Named Inventor	Ira Tabas	
INFORM	AATIC	N DISCLOSURE	CITATION	Art Unit	1647	
(Use sever	al sheets	if necessary)		Examiner Name	B.E. Bunner	
				Attorney Docket No.	0575/60921-A/JPV	W/MVM
		NON	PATENT LITERATURE DOC	CUMENTS	· · · · · · · · · · · · · · · · · · ·	
Examiner Initials	Cite No. ¹	Include name of the a item (book, magazine	uthor (in CAPITAL LETTERS), title of th e, journal, serial, symposium, catalog, etc.) publisher, city and/or country where	date, page(s), volume-issa	ate), title of the ue number(s),	T ²
	99	transporter	al. (2001) "Preferentia Al-mediated cholester sosomes," <i>J. Biol. Che</i> n	l ATP-binding ol efflux fr	com late	
	100	Christian, A	.E., et al. (1997) "Use cellular cholesterol c	e of cyclodext	rins for	
	101	of the ABC1	al. (2000) "Sterol-dep promoter by the liver . Biol. Chem. 275: 2824	X receptor/re	ctivation tinoid X	
	102	Fazio, S., et receptor-null <i>Invest</i> . 107:	al. (2001) "Increased mice lacking ACAT1 in 163-71	atheroscleros macrophages,"	is in LDL J. Clin.	
,	103	is defective Mechanism inv	al. (2002) "ABCA1-media in free cholestero volves enhanced ABCA1 de ll NPC1 activity," J. B	l-loaded macr gradation in a	ophages.	

et

levels," J. Clin. Invest. 108: 1315-1320

transported to

G.,

DATE CONSIDERED

Natl. Acad. Sci. U. S. A. 99: 407-412

104 expression of ABCA1 has minimal contribution to plasma HDL

Joyce C.W., et al. (2002) "The ATP binding cassette 105 transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice, " Proc.

Kellner-Weibel, G., et al. (1999) "Cytotoxic cholesterol 106 is generated by the hydrolysis of cytoplasmic cholesteryl

Khan, N., et al. (2003) "Plasma membrane cholesterol: A 108 possible barrier to intracellular oxygen in normal and mutant CHO cells defective in cholesterol metabolism,"

al.

al. (2001) "Monocyte/macrophage

the plasma

(1998)

membrane, "

"Effects

Haghpassand M.,

and

Biochemistry 42: 23-29

Kellner-Weibel,

EXAMINER

SIGNATURE

Atherosclerosis 146: 309-319

Thromb. Vasc. Biol. 18: 423-431

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

et

107 intracellular free cholesterol accumulation on macrophage viability: a model for foam cell death, " Arterioscler.

"Acid sphingomyelinase-

cholesterol

atherosclerosis,"

defective

et al. (1993) "The role of macrophages in

in

Page 11 of 13 Form PTO-1449 Substitute U.S. Department of Commerce Application Number 10/797,749 **Patent and Trademark Office** Filing Date January 28, 2004 First Named Inventor Ira Tabas INFORMATION DISCLOSURE CITATION Art Unit 1647 (Use several sheets if necessary) Examiner Name B.E. Bunner Attorney Docket No. 0575/60921-A/JPW/MVM NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite Examiner T^2 No.1 item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), Initials" publisher, city and/or country where published. Kolodgie, F.D., et al. (2000) "Localization of apoptotic macrophages at the site of plaque rupture in sudden 109 coronary death," Am. J. Pathol. 157: 1259-1268 Kruth, H.S., et al. (1984) "Histochemical detection and 110 differentiation of free and esterified cholesterol in swine atherosclerosis using filipin," Exp. Mol. Pathol. 40: 288-294 Lange, Y., et al. (1997) "Quantitation of the pool of cholesterol associated with acyl-CoA: cholesterol 111 acyltransferase in human fibroblasts, " J. Biol. Chem. 272: 13103-13108 Lange, Y., et al. (2000) "Cholesterol movement in Niemann-Pick Type C cells and in cells treated with amphiphiles," J. Biol. Chem. 275: 17468-17475 Lange, Y., et al. (1997) "The fate of cholesterol exiting 113 lysosomes, " J. Biol. Chem. 272: 17018-17022 Lange, Υ. (1992)"Tracking cell cholesterol cholesterol oxidase, " J. Lipid Res. 33: 315-321 114

have

trafficking and efflux," J. Biol. Chem. 276: 44976-44983

Liscum, L., et al. (1998) "Niemann-Pick disease type C,"

Lundberg, B. (1985) "Chemical composition and physical

Mallat, Z., et al. (1999) "Shed membrane microparticles

deposits

119 with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity," Circulation 99: 348-353 Marathe S., et al. (1998) "Human vascular endothelial 120 cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling, " J. Biol. Chem. 273: 4081-4088

EXAMINER SIGNATURE

DATE CONSIDERED

Leventhal A.R., et al. (2001)

lipid

117 Curr. Opin. Lipidol. 9: 131-135

Atherosclerosis 56: 93-110

of

macrophages

116 atherogenesis, " Curr. Opin. Lipidol. 4: 355-363

115 deficient

state

118

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Form PT	O-144	9 Substitute U.S. Department of Commerce	Application Number	10/797,749		
				January 28, 2004		
			First Named Inventor	Ira Tabas		
INFORM	IATIC	N DISCLOSURE CITATION	Art Unit	1647		
(Use severa	al sheets	if necessary)	Examiner Name	B.E. Bunner		
			Attorney Docket No.	0575/60921-A/JPW/MVM		
		NON PATENT LITERATURE DOC	UMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) publisher, city and/or country where	date, page(s), volume-issu published.			
	121	Mitchinson, M.J., et al. (199 atherosclerotic plaques," <i>Curr. Opin</i>	n. Lipidol. 7:			
	122	Rapp, J.H., et al. (1983) "Lipids of plaques and xanthomas: clues to th progression," <i>J. Lipid Res.</i> 24: 132	e mechanism o			
	123	Ross, R. (1995) "Cell biology of at Rev. Physiol. 57: 791-804				
	124	Schissel, S.L., et al. (1998) "Secre a product of the acid sphingomyelina atherogenic lipoproteins at neutral atherosclerotic lesion development, 2738-2746	se gene, can h . pH. Implicat	nydrolyze ions for		
	125	Mitchinson, M.J., et al. (199 atherosclerotic plaques," <i>Curr. Opin</i>	6) "Cell de n. Lipidol. 7:			
	126	Sparrow, S.M., et al. (1999) intracellular cholesterol transport release in human neuroblastoma cells 69-77	and neurotra			
	127	Tabas, I. (2000) "Cholesterol and pl in macrophages," <i>Biochim. Biophys</i> .	hospholipid me Acta 1529: 16	tabolism 4-174		
	128	Tabas, I. (2002) "Consequences of accumulation: basic concepts implications," <i>J. Clin. Invest.</i> 110	and physi : 905-911	ological		
	129	Tall, A.R. (1998) "An overview of transport," <i>Eur. Heart J.</i> A31-A35	reverse cho	lesterol		
	130	atherosclerotic lesions of apoling mice, " Proc. Natl. Acad. Sci. U.S.A	n macrophage poprotein E-d 1. 99: 2234-22	es from eficient 39		
	Underwood, K.W., et al. (1998) "Evidence for a cholesterol transport pathway from lysosomes to endoplasmic reticulum that is independent of the plasma membrane," J. Biol. Chem. 273: 4266-4274					
EXAMINE SIGNATUI		DATE CONSIDERED				

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 Substitute

U.S. Department of Commerce Application Number Patent and Trademark Office Filing Date

Application Number 10/797,749 Filing Date January 28, 2004 First Named Inventor Ira Tabas Art Unit 1647

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

SIGNATURE

Examiner Name	B.E. Bunner
Attorney Docket No.	0575/60921-A/JPW/MVM

		precoracy Docket Ivo.	
	,	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	132	Underwood, K.W., et al. (1996) "Quantitative analysis of hydrophobic amine inhibition of intracellular cholesterol transport," J. Lipid Res. 37: 1556-1568	
	133	Vaisman, B.L., et al. (2001) "ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice," J. Clin. Invest. 108: 303-309	
	134	van Eck, M., et al. (2002) "Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 99: 6298-6303, E-published 2002 Apr 23	
	135	Wang, Y., et al. (2002) "Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1," J. Biol. Chem. 277: 5692-5697	
	136	Williams, K.J., et al. (1995) "A reexamination of the NRMP matching algorithm. National Resident Matching Program," Arterioscler. Thromb. Vasc. Biol. 15: 551-561	
	137	Yancey, P.G., et al. (1996) "Cellular cholesterol efflux mediated by cyclodextrins. Demonstration Of kinetic pools and mechanism of efflux," J. Biol. Chem. 271: 16026-16034	
·	138	Yao, P.M., et al. (2000) "Free cholesterol loading of macrophages induces apoptosis involving the fas pathway," J. Biol. Chem. 275: 23807-23813	
	139	Yao, P.M., et al. (2001) "Free cholesterol loading of macrophages is associated with widespread mitochondrial dysfunction and activation of the mitochondrial apoptosis pathway," J. Biol. Chem. 276: 42468-42476	<u>.</u>
	140	Yeagle, P.L. (1991) "Modulation of membrane function by cholesterol," <i>Biochimie</i> 73: 1303-1310	
		Zhang, D., et al. (2000) "Macrophages deficient in CTP: Phosphocholine cytidylyltransferase-alpha are viable under normal culture conditions but are highly susceptible to free cholesterol-induced death. Molecular genetic evidence that the induction of phosphatidylcholine biosynthesis in free cholesterol-loaded macrophages is an adaptive response," J. Biol. Chem. 275: 35368-35376	
	142	Kapczinski, F., et al. (2003) "Antidepressants for generalized anxiety disorder," Cochrane Databse Syst. Rev. 2003:CD003592, abstract	
EXAMINE	\	DATE CONSIDERED	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'Applicant is to place a checkmark here if English language Translation is attached.